Related references
Note: Only part of the references are listed.Estimating the global burden of Epstein-Barr virus-related cancers
Yide Wong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis
[Anonymous]
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma
Shazia Nakhoda et al.
CANCERS (2022)
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Kjetil Bjornevik et al.
SCIENCE (2022)
Targeting the PD-1/PD-L1 interaction in nasopharyngeal carcinoma
David Johnson et al.
ORAL ONCOLOGY (2021)
EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer
Samantha S. Soldan et al.
GASTRIC CANCER (2021)
Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma
Saidu Kamara et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2021)
Landscape of EBV-positive gastric cancer
Motonobu Saito et al.
GASTRIC CANCER (2021)
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1
Julius Maximilian Knerr et al.
CANCERS (2021)
Small molecule screening identifies inhibitors of the Epstein-Barr virus deubiquitinating enzyme, BPLF1
Sage L. Atkins et al.
ANTIVIRAL RESEARCH (2020)
Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma
Jin Zhao et al.
CANCER LETTERS (2020)
Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase
Natalia C. Drosu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Biophysical Screens Identify Fragments That Bind to the Viral DNA-Binding Proteins EBNA1 and LANA
Troy E. Messick et al.
MOLECULES (2020)
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
Constanze Slabik et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies
Angela Kwok-Fung Lo et al.
CANCERS (2020)
Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future
Stephanie Pei Tung Yiu et al.
CANCERS (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review
Klemens Ruprecht
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)
Tenofovir as a treatment option for multiple sclerosis
Oivind Torkildsen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
Anna Christina Dragon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer
Akihito Kawazoe et al.
GASTRIC CANCER (2019)
CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo
Leonardo Chicaybam et al.
HUMAN GENE THERAPY (2019)
Novel Therapeutics for Epstein-Barr Virus
Graciela Andrei et al.
MOLECULES (2019)
Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
Troy E. Messick et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells
Wei Bu et al.
IMMUNITY (2019)
Development of a novel inducer for EBV lytic therapy
Nadezhda Tikhmyanova et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL
Yasuo Takashima et al.
SCIENTIFIC REPORTS (2019)
Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein-Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth
Krzysztof Wojtak et al.
VACCINES (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
The Global Landscape of EBV-Associated Tumors
Claire Shannon-Lowe et al.
FRONTIERS IN ONCOLOGY (2019)
Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma
Stephanie Pei Tung Yiu et al.
CANCERS (2019)
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
DRUG SAFETY (2019)
Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation
Suzan Fares et al.
MBIO (2019)
Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity
Adam Z. Cheng et al.
NATURE MICROBIOLOGY (2019)
Thymidine kinase and protein kinase in drug-resistant herpesvirtises: Heads of a Lernaean Hydra
Dimitri Topalis et al.
DRUG RESISTANCE UPDATES (2018)
Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma
Denis Terziev et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology-Mechanisms of Disease (2018)
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Lauren P. McLaughlin et al.
BLOOD (2018)
CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal
Lei Lei et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice
Dwain G. van Zyl et al.
PLOS PATHOGENS (2018)
Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein-Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers
Stephanie Pei Tung Yiu et al.
CANCERS (2018)
Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model
Yushi Qiu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers
Lijun Jiang et al.
THERANOSTICS (2018)
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Varicella and herpes zoster vaccine development: lessons learned
Charlotte Warren-Gash et al.
EXPERT REVIEW OF VACCINES (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma
Marc L. Ooft et al.
ORAL ONCOLOGY (2017)
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
English D. Willis et al.
VACCINE (2017)
Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation
Nadezhda Tikhmyanova et al.
PLOS PATHOGENS (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Epstein-Barr Virus-Specific Adoptive Immunotherapy for Recurrent, Metastatic Nasopharyngeal Carcinoma
Julian Huang et al.
CANCER (2017)
Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir
Kwai Fung Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Computational analysis of EBNA1 druggability suggests novel insights for Epstein-Barr virus inhibitor design
Eleonora Gianti et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2016)
Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
Xinle Cui et al.
VACCINE (2016)
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Sarah Derks et al.
ONCOTARGET (2016)
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Masaru Kanekiyo et al.
CELL (2015)
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma
Sharon D. Stoker et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification of a New Class of Small Molecules That Efficiently Reactivate Latent Epstein-Barr Virus
Nadezhda Tikhmyanova et al.
ACS CHEMICAL BIOLOGY (2014)
EBNA1-specific luminescent small molecules for the imaging and inhibition of latent EBV-infected tumor cells
Lijun Jiang et al.
CHEMICAL COMMUNICATIONS (2014)
Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
Whay-Kuang Chia et al.
MOLECULAR THERAPY (2014)
Switching of EBV cycles between latent and lytic states
Takayuki Murata et al.
REVIEWS IN MEDICAL VIROLOGY (2014)
Modes of infection and oncogenesis by the Epstein-Barr virus
Takayuki Murata et al.
REVIEWS IN MEDICAL VIROLOGY (2014)
Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
Vanya Icheva et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
EBV BILF1 Evolved To Downregulate Cell Surface Display of a Wide Range of HLA Class I Molecules through Their Cytoplasmic Tail
Bryan D. Griffin et al.
JOURNAL OF IMMUNOLOGY (2013)
Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine
W. Li et al.
ACTA VIROLOGICA (2013)
Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization
Sun Young Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy
Corey Smith et al.
CANCER RESEARCH (2012)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production
Qiao Meng et al.
JOURNAL OF VIROLOGY (2010)
Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors
Jill K. Countryman et al.
JOURNAL OF VIROLOGY (2008)
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Susan R. Perrine et al.
BLOOD (2007)
Treatment of solid organ transplant recipients with autologolus Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Barbara Savoldo et al.
BLOOD (2006)
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes
P Comoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide
CJ Farrell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma
P Comoli et al.
ANNALS OF ONCOLOGY (2004)
Promoter sequences required for reactivation of Epstein-Barr virus from latency
UK Binné et al.
JOURNAL OF VIROLOGY (2002)
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle
L Gradoville et al.
JOURNAL OF VIROLOGY (2002)
Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies
DV Faller et al.
CURRENT OPINION IN ONCOLOGY (2001)
Share Paper
